Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Characteristic N = 51
Age, n (%)
  <65 years 28 (54.9)
  ≥65 years 23 (45.1)
 Median (range), years 64.0 (31–84)
Sex, n (%)
 Male 34 (66.7)
 Female 17 (33.3)
Race, n (%)
 White 35 (68.6)
 Asian 2 (3.9)
 American Indian or Alaskan 1 (2.0)
 Black or African American 1 (2.0)
 Other 12 (23.5)
ECOG performance status, n (%)
 0 25 (49.0)
 1 26 (51.0)
Site of primary tumor, n (%)
 Cutaneous 28 (54.9)
 Ocular 16 (31.4)
 Mucosal 2 (3.9)
 Othera 5 (9.8)
Time from initial diagnosis to study entry, years  
 Median 4.3
 Range 0.3–33.5
Time since first metastatic disease, months
 Median 14.8
 Range 2.3–168.9
PD-L1 expression (≥1% of tumor cells), n (%)
 Positive 19 (37.3)
 Negative 20 (39.2)
 Not evaluable 12 (23.5)
Number of prior lines of therapy for metastatic or locally advanced disease, n (%)
 0 1 (2.0)
 1 23 (45.1)
 2 17 (33.3)
  ≥3 9 (18.0)
 Missing 1 (2.0)
 Median (range) 2 (0–4)
Prior anticancer therapy in >5% of patients, n (%)
 Ipilimumab 26 (51.0)
 Dacarbazine 11 (21.6)
 Cisplatin 8 (15.7)
 Interferon 6 (11.8)
 Fotemustine 5 (9.8)
 Gemcitabine 5 (9.8)
 Treosulfan 5 (9.8)
 Vemurafenib 5 (9.8)
 Investigational drug 4 (7.8)
 Paclitaxel 3 (5.9)
 Sorafenib 3 (5.9)
  1. a Includes melanoma of the canthus (n = 1) and unknown primary (n = 4)